InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,442.00
(
2.14%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,999.72
(
0.18%
)
Post# of 251704
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119566
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 119026

Thursday, 04/28/2011 3:57:58 PM

Thursday, April 28, 2011 3:57:58 PM

Post# of 251704
I would characterize the CATT results as a commercial victory for Roche and NVS. The lower frequency of SAE’s in the Lucentis arm missed statistical significance (using a 2-sided 95% CI) by a whisker with an HR of 0.775 (1/1.29). This combined with the CATT retinal-thickness data (which were statsig in favor of Lucentis) and the data from the Johns Hopkins/Medicare study (#msg-61713973) make a strong case for Lucentis, IMO.

Blindness isn’t something doctors should want to risk just to save some money for the healthcare system.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up